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Aim: To evaluate the influence of socioeconomic and demographic factors on the eradication rate of H. pylori, using standard triple 
therapy 
Background: the efficacy of the standard triple therapy (STT) for H. pylori eradication has decreased with the rise of antibiotic 
resistance. Other factors could influence the eradication failure, although available results are conflicting. 
Methods: Retrospective study, including adults with H. pylori infection treated de novo with STT (proton pump inhibitor, amoxicillin 
and clarithromycin). Eradication success was assessed by 13C-urea breath test. Demographic and socioeconomics variables were 
evaluated and correlated with eradication treatment outcome. The confounder variables were controlled by logistic regression 
analysis.  
Results: Out of 902 patients with H. pylori diagnosis, 693 met inclusion criteria (average age 53 years; females 55.2%). Non-
significant differences were observed in relation to economics income between rural and urban areas (p=0.316). The eradication rate 
of H. pylori was 71.1%: male 78.9% vs female 65.9%, urban area 73.4% vs rural area 64.1%. With reference to age, income and 
nationality, the eradication rates were similar in all groups. According to logistic regression analysis, females had almost twice more 
likelihood of eradication failure in relation to males (OR 1.92; 95%CI: 1.38–2.72); and rural residents had OR 1.55 (95%CI: 1.03–
2.33) for having eradication failure in contrast with urban population.   
Conclusion: Female gender and rural residence are factors associated with H. Pylori eradication failure with standard triple therapy.  
Keywords: Helicobacter pylori, Demographic factors, Socioeconomic factors, Eradication failure, Standard triple therapy. 
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Introduction  
  1 Helicobacter pylori (H. pylori) is a gram-negative 
bacterium able to colonize the gastric and duodenal 
mucosa provoking inflammation and immune response, 
with pH alteration. It has been related to the appearance 
of gastric atrophy and intestinal metaplasia, peptic ulcer 
disease, gastric adenocarcinoma and low-grade 
malignant B-cell lymphoma (1). According to 
worldwide estimations, H. pylori infection affects 
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around 44.3% of the general population (95%CI: 40.9-
47.7%), being more prevalent in developing countries 
(2,3). Epidemiological studies show higher infection 
rate in populations with elevated percentage of multi-
ethnic immigration, and inversely proportional to 
economic level, education and the quality of potable 
water (4,5). 
The standard triple therapy (STT) has been the regimen 
preferentially used to eradicate the H. pylori infection. 
It is based on the association of proton pump inhibitors 
(PPI) with two antibiotics: amoxicillin and 
clarithromycin. This combination is still successfully 
used in areas with low resistance to clarithromycin 
(<15%) (6-11). Nevertheless, there are factors which 
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can reduce the eradication rate, the best known being 
the drug combination, the time of treatment, the 
adhesion to the therapy, and the resistance to 
clarithromycin in the population (12). Other conditions 
like demography or clinical and socio-economics 
features, which can result in a reduction of the 
treatment effectiveness, are also proposed. This group 
includes gender, age, ethnicity, profession, 
socioeconomic status, tobacco smoking, alcohol 
consumption, body mass index, comorbidity, previous 
consumption of antibiotics, and some genetic as well as 
geographical determinants (13-21). Even so, the results 
vary widely around the world. 
In some studies with Asian populations (13,14,18) 
including more than 5200 patients treated with STT, it 
was concluded after a multivariant analysis that some 
professions (especially farmers) and female gender 
show less treatment success. Kim et al. (14) defined an 
odds ratio (OR) of 1.69 for the failure in woman and an 
OR of 1.61 for smokers. These results have not been 
confirmed in another recent study in the American 
population (22), where the only factor which could 
reduce the eradication rate was the exposition to 
antibiotics for the six months prior to the treatment. 
Considering everything mentioned, there is a clear need 
for new studies to clarify which factors are associated 
with the failure of the treatment, or which population is 
at higher risk. Along these lines, we began to 
investigate a population with higher resistance to 
clarithromycin if it is possible to define socioeconomic 
and demographic factors that would determine 
differences in the eradication rate of H. pylori, using 
the STT.   
 
Methods 
Design and study population 
A retrospective study in two Spanish health areas (380 
718 and 109 438 inhabitants, respectively) was carried 
out. Adult patients (more than 18 years old) with de 
novo diagnosis of H. pylori, treated with STT and re-
evaluated after treatment, were enrolled. 
Evaluation and treatment of H. pylori infection 
The diagnosis of H. pylori infection was considered 
with 13C-Urea Breath Test (UBT) positive. The STT 
regimen was amoxicillin 1gr/12h, clarithromycin 500 
mg/12h and Omeprazole 20mg/12h, for 7 days. The 
eradication was evaluated by 13C-UBT at least 4 weeks 
after the conclusion of eradication treatment, no later 
than 12 months. 
Variables 
The demographic variables assessed were gender, age 
and nationality. The socioeconomic ones were income 
and urban or rural residence. The eradication result 
(value of the 13C-UBT post-treatment) was also 
determined. The demographic information was 
collected from the patient individual electronic clinical 
records. The urban/rural origin was established based 
on the address post-code of each patient. An urban area 
was considered as that with more than 10 000 
inhabitants (according to Spanish Statistic Institute and 
Geography National Institute criteria). The economic 
status was estimated from the six categories ranking 
(001 to 006) that is shown in the Individual Spanish 
Health Card (ISHC). This classification corresponding 
with the increasing rate of pharmaceutical contribution, 
is in turn directly related with the level of income (001 
the lowest and 006 the highest). 
Statistical analysis 
The data were analysed using the Pearson chi-squared 
test (2) to assess the correct distribution of the 
variables. In order to develop a multivariate analysis, 
the variables with multiple categories were 
dichotomized. For age, the cut point was the average 
age, being 18-52=0 and 53 or more=1. The yearly 
income was coded as 0 for 12001 euros or more and 1 
for the annual income of less than 12001 euros. The 
nationality was defined as Spanish=0 and others=1. 
With reference to gender, being a woman was 
considered as the risk factor. These variables were 
related to H. pylori eradication using the odds ratio 
(OR) with 95% confidence interval (CI) to measure the 
association. A logistic multiple regression model was 
adopted to control the confounder variables. Statistical 
significance was set at p-value<0.05.  
Ethics 
The data of the study were strictly confidential and only 
the researchers had access to them, according to the 
Spanish personal data protection law. The study was 
carried out in accordance with the principles of the 
1975 Declaration of Helsinki (6th revision, 2008). The 
protocol study was approved by the Regional Ethics 
Committee (CEIC Aragon: C.P. - C.I. PI18/360). 
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Results 
A total of 902 patients had a positive 13C-UBT, and 
209 were excluded (23.2%) for the following reasons: 
133 did not have a second UBT, 57 were treated with a 
regimen different from STT, and 19 had a different 
method of evaluating eradication to 13C-UBT (Figure 1). 
 
Figure 1. Patients’ Flowchart 
 
Six hundred and ninety-nine patients were finally 
enrolled. The average age was 53 years old (range 18-83); 
55.2% were women and 44.8% men. After stratifying 
the gender by age groups and income, no statistical 
differences were observed (p=0.814 and p=0.646, 
respectively). However, we found differences in the 
gender distribution according to nationality (p=0.028), 
with the male gender being more frequent among the 
cases from Africa, Asia and Eastern Europe and the 
female among Latin American patients. The main 
nationality was Spanish, representing 82.7% (men 
83.4% and women 82.1%). Regarding urban/rural 
distribution, our results shown differences among age 
groups and nationalities (p=0.026 and p<0.001, 
respectively). In the urban area, the Latin American 
immigrant population was more frequent, while in the 
rural area it was the African origin. With regards to 
income, no differences were observed between urban 
and rural population (p=0.440) (Table 1). 
The global eradication rate of H. pylori in our 
patients was 71.1% (95%IC 68.5-74.9), being higher in 
men [78.9% (95%IC 74.0-83.1)] than in women [65.9% 
(95%IC 61.1-70.5)]. After comparing the urban/rural 
origin, we observed that the urban area had an 
eradication rate of 73.4% (95%IC 69.7-76.9) being 
almost 10% higher than that achieved in rural area, 
64.1% (95%IC 55.5-71.8). In relation to age, income 
and nationality, the percentage of eradication was 
similar among the study groups (Table 2). The logistic 
regression analysis concluded that women were almost 
twice as likely for the eradication failure in comparison 
with men (OR 1.92; 95%IC 1.38-2.72). Additionally, 
the rural population showed 55% more eradication 
failure in contrast with urban population (OR 1.55; 
95%IC 1.03-2.33). In our study, the variables of age, 
income and nationality were not associated with 
therapeutic failure (Table 2). 
 
Discussion 
In the present study, results were obtained in favour 
of the existence of socioeconomic determinants 
associated to H. pylori eradication failure using STT. In 
the geographical area where the study was carried out, 
other authors have noticed a clarithromycin resistance 
of higher than 15%8. This may justify the 71% of 
therapeutic efficacy in the analysed sample, lower than 
the standards considered acceptable to an eradicator 
regimen for the bacteria. In addition, after evaluating 
902 patients 
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other possible factors involved, we observed that upon 
logistic regression analysis, including factors of age, 
gender, income, nationality and area of living, being a 
woman and living in a rural area could decrease the 
success of H pylori eradication in an independent way. 
The female gender in our study showed a risk of 
therapeutic failure almost twice the rate of male gender 
(OR 1.98; 95%CI 1.39-2.80). This is consistent with 
results of a systematic world revision which concludes 
that the average resistance rate to clarithromycin was 
20.5% in women versus 15.5% in men, the difference 
being statistically significant (p<0.001; OR 1.4, 95%IC 
1.2-1.5) (23). A study developed in the Spanish 
southern population also observed an association 
between female gender and H. pylori clarithromycin 
resistance (OR 1.71; 95%IC 1.007-2.913) (15). In the 
same vein, several recent studies performed in Asian 
population have found that the risk of eradication 
failure is lower among females, with OR 1.69 to 1.73 
(18-20). Conversely, some authors evaluating 
Table 1. Distribution by gender and living place urban/rural of the study variables 
Variables Total Male Female p-value‡  Urban Rural p-value ‡ 
n (%) n (%) n (%)  n (%) n (%) 
Stratified age 
18 – 25 
26 – 35 
36 – 45 
46 – 55 






















































































































Total 693 (100.0) 308 (100.0) 385 (100.0)   565 (100.0) 128 (100.0)  
‡Chi square. †ISHC: Individual Spanish Health Care (code of pharmaceutical, contribution directly related with the the level of income). *p<0.05 
 
Table 2. Univariate analysis and logistic regression to determine the association between socio-demographic variables and H 
pylori eradication failure with STT (n=693). 
Variables Positive Eradication Crude OR CI95% Adjusted OR† CI95% 





















1.39 – 2.80 
Age 
18 – 52 years 

















































































1.05 – 2.41 
†Logistic regression analysis. Ref: Reference value. * ISHC codes 001 and 003 (corresponding to non-contributory pensions and yearly income 
lower than 18.000€). **Other ISHC codes (corresponding to contributory pensions, civil servants and yearly income higher than 18.000€) 
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populations with lower rate of clarithromycin resistance 
could not conclude that gender was a risk factor 
involved in the resistance, or influences the eradication 
therapy success, when STT regimen is used (22).  
The results are difficult to explain in this area of 
research. In Navarro-Jarobo et al. (15) study, genetic 
mutations associated with clarithromycin resistance 
(essentially A2143G in 82.3% and A214G in 7.1% of 
the cases) were detected in a related population, but the 
authors could not define the gender distribution of these 
mutations. In a Korean population, Hwang et al. (24) 
had previously revealed that mutation A143G was 
related to H. pylori eradication failure in 87.5% of 
patients treated with triple therapies containing 
clarithromycin. Additionally, this gene was mainly 
expressed among females. Recognising potential 
genetics factors, other studies found differences in the 
biologic behaviour of genetic metabolizer of CYP2C19 
regarding gender, but it could not be unequivocally 
linked with the result of the eradication (17,19). 
Examining other potential causes, it is proposed that 
the more frequent use of antibiotics among women, 
essentially to solve urinary or gynaecologic infections, 
could justify the results. In fact, the previous use of 
macrolides, especially during time periods longer than 
two weeks, is associated with eradication failure.18 
Furthermore, a study in a Northern Canadian 
population (25) showed worse compliance of treatment 
among women compared with men, although no 
multivariate analysis was performed to exclude bias. 
The adherence to the eradication therapy is an essential 
factor for its success (26). However, it cannot be 
assessed with accuracy in our study due to its 
retrospective design, hence unduly affecting the results. 
After analysing the role of the variable of place of 
living, we have obtained a rise in the eradication failure 
in rural population as contrasted to urban inhabitants 
(OR 1.59; 95%IC 1.05-2.41). Nevertheless, the variable 
acts heterogeneously in the limited publications that 
research it. While in China, Cai et al.13 found that 
farmers compared to civil servants had ten times the 
likelihood of failure in the eradication treatment with 
STT, in Korea, Kim et al. (14) did not find differences 
in the function of the living place variable. However,  
there is some additional information published which 
could be related to poorer therapeutic performance in 
rural areas. The transmission of the bacteria in urban 
area seems to occur basically from person to person, 
while in rural populations, water and contaminated 
food are added as likely transmission routes (27). 
Perhaps for similar reasons, the infection and 
reinfection are more frequent too (28,296). According 
to our findings, factors like age distribution and income 
could not explain the differences.  
In this study, we evaluated the effectiveness of the 
eradication treatment with STT in both populations, 
rural and urban, analysing the influence of the socio-
demographic factors rarely addressed so far, especially 
in a non-Asian population. As has been mentioned 
above, the retrospective design does not allow to 
provide a random sampling of the population in order 
to reduce the potential bias. On the other hand, 
although the antimicrobial resistance in our population 
is presumably high, according to the information in 
nearby geographical areas, this topic was not assessed 
in the patients enrolled in the study before the 
eradication treatment. 
In a geographical area where H. pylori eradication 
rate with STT is lower than 80%, the female gender and 
living in a rural area are potential individual risk factors 
associated with therapeutic failure. This could have 
repercussions in the antibiotic pattern choice in certain 
groups of patients. Further prospective studies are 
needed to ensure if the same factors could affect the 
effectiveness of other therapeutic regimens. 
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